cTRL Therapeutics Presents Groundbreaking Data at SITC Annual Meeting
cTRL Therapeutics is gearing up to reveal innovative and promising data about its cTRL platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The presentation aims to showcase exciting developments in cell therapies specifically designed to combat solid tumors, a challenging area in cancer treatment.
Highlighting the Potential of cTRLs
With the upcoming poster presentations, cTRL Therapeutics intends to shine a light on how circulating tumor-reactive lymphocytes (cTRLs) can address longstanding challenges faced by standard solid tumor therapies. The aim is to present compelling evidence on the efficacy of cTRLs, which are derived through their proprietary IsoQore™ platform, known for isolating and expanding lymphocytes directly from a patient's blood.
Details of cTRL's Presentations
The company’s poster presentations are highly anticipated and will include significant findings regarding patients who have previously encountered difficulties with traditional treatments.
- Title: Anti-tumor activity of circulating tumor-reactive lymphocytes (cTRLs) isolated from checkpoint-refractory melanoma patients that failed TIL manufacturing.
- Abstract Number: 401
- Date and Time: Friday, November 8, from 9:00 a.m. to 7:00 p.m. CST
- Location: Exhibit Halls A & B, George R. Brown Convention Center
- Title: Circulating tumor-reactive lymphocytes (cTRLs) isolated from colorectal cancer (CRC) patients are reactive against autologous tumors and show less exhaustion than tumor-infiltrating lymphocytes (TILs).
- Abstract Number: 400
- Date and Time: Saturday, November 9, from 9:00 a.m. to 7:00 p.m. CST
- Location: Exhibit Halls A & B, George R. Brown Convention Center
About cTRL Therapeutics
cTRL Therapeutics is leading the charge in redefining cancer treatment with its innovative IsoQore™ platform that focuses on solid tumors. Their primary product, cTRL-001, is designed as a scalable solution ready for outpatient treatment, enabling faster and wider patient access to vital therapies. As the company progresses through their clinical pipeline, they continue their commitment to enhancing the availability of pivotal cancer treatments.
In Conclusion
The upcoming SITC Annual Meeting represents a significant milestone for cTRL Therapeutics. The focus on circulating tumor-reactive lymphocytes holds immense promise and could potentially revolutionize the way solid tumors are treated. As they prepare for these presentations, the company stands at the forefront of a dynamic shift in cancer therapy methodology, aiming for a brighter future for patients facing solid tumors.
Frequently Asked Questions
What is the focus of cTRL Therapeutics' presentation at the SITC Annual Meeting?
cTRL Therapeutics will present findings related to the efficacy of circulating tumor-reactive lymphocytes (cTRLs) in treating solid tumors.
Where will the presentations take place?
The poster presentations will be held at the George R. Brown Convention Center, specifically in Exhibit Halls A & B.
What is the IsoQore™ platform used for?
The IsoQore™ platform is utilized to isolate and expand circulating tumor-reactive lymphocytes from peripheral blood, offering a promising treatment modality for solid tumors.
When are the scheduled presentation dates?
The presentations are scheduled for November 8 and 9, 2024.
What distinguishes cTRL-001 from other therapies?
cTRL-001 is designed to be scalable and suitable for outpatient settings, enhancing patient accessibility to cutting-edge treatments for solid tumors.
